Imprint(TM) ChIP Kit Offers a Complete Solution for the Study of
ST. LOUIS, April 16 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL) today announced the launch of its Imprint(TM) Chromatin Immunoprecipitation Kit for epigenetic research (http://www.sigma.com/chip). The Imprint(TM) ChIP Kit provides a complete solution for Chromatin Immunoprecipitation, including columns and reagents for DNA purification as well as an integrated protocol for ChIP DNA amplification with the GenomePlex(R) Whole Genome Amplification Kit. This flexible format allows for immunoprecipitation and purification of DNA from mammalian cells or tissue in a convenient microwell format.
ChIP is an innovative technology that enables scientists to investigate complex DNA-protein interactions in vivo, potentially increasing the speed and accuracy of disease research and drug discovery. The Imprint(TM) ChIP Kit provides researchers with rapid and accurate results, enabling high-throughput, same-day downstream analyses via quantitative PCR, MS-PCR, and DNA sequencing as well as DNA microarray. With the shortest protocol time and highest throughput capabilities on the market, the Imprint(TM) ChIP Kit, offers significant time and cost savings to epigenetic researchers.
"Sigma's Imprint(TM) ChIP Kit incorporates all of the requirements for Chromatin Immunoprecipitation procedures," said Tim Fleming, Director of Global Commercial Marketing for Sigma-Aldrich Life Science. "These integrated tools will help researchers better understand complex protein networks and expedite epigenetic research and development."
The Imprint(TM) ChIP Kit complements Sigma Life Science's robust product line to support the epigenetic workflow, including the Imprint(TM) DNA Modification Kit as well as products for DNA purification, qPCR, sequencing and post-reaction clean-up. The Imprint(TM) ChIP Kit is based on Chromatin Immunoprecipitation (ChIP) technology licensed from Epigentek Group.
"This arrangement reinforces Epigentek's leading position in the epigenetic arena," said Adam Li, Chief Scientific Officer for Epigentek. "We share Sigma's commitment to developing the next generation of research tools for epigenetic research."
About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use our products. Sigma-Aldrich operates in 36 countries and has 7,900 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit our award-winning website at http://www.sigma-aldrich.com.
About Epigentek Group Inc: Epigentek Group Inc. is a biotechnology company that focuses on developing and providing innovative technology and products as a complete and systematic solution for epigenetics-related research and drug discovery. The company has developed a comprehensive portfolio of more than 400 proprietary products that are used all around the world by esteemed academia, leading pharmaceuticals, and cutting edge biotechnology companies. These unique products are specifically designed to make assays significantly more simple, fast, convenient and efficient than conventional methods. The company, particularly emphasizing speed and effectiveness in its technologies, continues to focus on epigenetic innovation and to extensively develop and enhance its product portfolio.
Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Companies' expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Companies' operations and conditions in the markets the Companies serve. The Companies do not undertake any obligation to update these forward-looking statements.
Copyright©2008 PR Newswire.
All rights reserved